15 Sep 2014
73° Clear
Patch Instagram photo by daniellemastersonbooks
Patch Instagram photo by longunderwearman
Patch Instagram photo by quadrofoglio
Patch Instagram photo by athomeinmygarden
Patch Instagram photo by daniellemastersonbooks
Patch Instagram photo by healthandbeautynz
Patch Instagram photo by andreagazeapt
Patch Instagram photo by reh_22
Patch Instagram photo by athomeinmygarden

BioMarin Starts New Year With Big Move

Marin pharmaceutical company acquires San Diego-based Zacharon Pharamaceuticals for $10 million.

BioMarin Starts New Year With Big Move

San Rafael's BioMarin Pharmaceutical Inc. announced Monday that it has acquired Zacharon Pharmaceuticals, a private biotechnology company based in San Diego.

Hank Fuchs, M.D., Executive Vice President and Chief Medical Officer of BioMarin said, "Zacharon's lead program, focused on reducing the accumulation of heparan sulfate, offers the exciting prospect of treating both the CNS and peripheral manifestations of MPS III, and potentially other MPS disorders, with an orally bioavailable small molecule. In general, reducing the synthesis of the target substrate alleviates the burden on the compromised lysosomal system, and this therapeutic approach has been clinically validated with other enzyme inhibitors. Zacharon's deep expertise in glycobiology has generated
additional programs for treating lysosomal storage disorders that we expect to progress, and we will leverage that expertise to continue to build BioMarin's existing research and development pipeline into a sustainably leading pipeline."

"The acquisition of Zacharon will further expand our glycobiology expertise and will support our lysosomal storage disease drug development efforts," said Jean-Jacques Bienaime, Chief Executive Officer of BioMarin. "We are committed to investing in our advancing pipeline, which has evolved through a combination of internal development and targeted acquisitions, such as this."

Under the terms of the stock purchase agreement, BioMarin, which develops bio-pharmaceuticals for diseases and medical conditions, paid $10 million upfront for 100 percent of Zacharon's share capital and may make potential additional payments for clinical, regulatory and commercial milestones. The costs to be incurred in 2013 of acquiring Zacharon and absorbing its operations is covered by the previously provided 2013 R&D expense guidance.

Like us on Facebook / Follow us on Twitter and Foursquare /
Register for our free newsletter

Share This Article